Biotech Startups

Cardiac Booster develops cardiac support technology for use in treating heart conditions. The company operates in the medical device sector.

2 investors

CardioFocus develops Pulsed Field Ablation (PFA) technologies and systems for electrophysiologists to treat complex cardiac arrhythmias with precision and control. The company's portfolio includes the Centauri™ System and next-generation platforms designed for diverse ablation strategies in electrophysiology practices worldwide.

2 investors

CasInvent Pharma develops pharmaceutical solutions, currently raising Series A funding through a crowdfunding campaign.

2 investors

Castle Creek Biosciences develops re-dosable gene therapies for genetic diseases, with a lead candidate (D-Fi) in registrational clinical trials for dystrophic epidermolysis bullosa.

2 investors

Catalyst OrthoScience develops medical devices and surgical techniques for shoulder replacement procedures, including total shoulder replacements and reverse shoulder arthroplasty. The company serves orthopedic surgeons and hospitals aiming to improve patient outcomes and surgical efficiency.

2 investors

Catamaran Bio develops allogeneic CAR-NK cell therapies for cancer treatment, focusing on solid tumors, by combining natural killer (NK) cell biology with synthetic biology and non-viral cell engineering. Its proprietary TAILWIND platform is used to engineer, expand, and process NK cells into cell therapy products.

2 investors

CatenaBio develops precision conjugation technology using native amino acids to enable biotherapeutic fusions of small molecules, nucleic acids, enzymes, and cells. The company partners with pharmaceutical firms to advance development of novel therapeutic modalities.

2 investors

A biotech company associated with immunology and cellular research, listing medical and scientific advisors. The specific products or services offered are not described on the page.

2 investors

Cayuga Biotech is a clinical-stage biotechnology company developing therapeutics for hemorrhage and blood-clotting-related conditions, with a lead candidate CAY001. It focuses on the hemostasis and thrombosis space, drawing on materials chemistry and translational medicine.

2 investors

Cebiotex is a biotech company developing innovative pharmaceutical products using proprietary nanofiber-based drug delivery technology, with a focus on oncology and surgical applications. The company pursues a partnership and licensing model with pharmaceutical firms to scale and distribute therapies globally.

2 investors

Cedience provides a SaaS platform that uses natural language processing and machine learning to help drug development teams quickly find evidence-backed answers to regulatory questions by centralizing and integrating regulatory databases. The platform serves pharmaceutical and biotech companies navigating drug development and regulatory approval processes.

2 investors

Celaid Therapeutics develops hematopoietic stem cell expansion technology, including a method to replace albumin with polyvinyl alcohol and to expand human hematopoietic stem cells ex vivo in large quantities. The company applies this technology to stem cell transplantation and gene therapy for blood cancers such as leukemia and other blood and genetic diseases.

2 investors

Celcuity is a commercial-stage biotechnology company developing targeted cancer therapies for tumors involving the PAM (PI3K/AKT/mTOR) pathway, including breast, prostate, lung, endometrial, colon, and ovarian cancers. Its lead candidate, gedatolisib, targets all Class I PI3K isoforms and the mTORC1 and mTORC2 complexes and is being evaluated across multiple oncology clinical programs.

2 investors

Cell Microsystems develops automated instruments for cellular and molecular workflows used in life science research, including oncology, stem cell biology, and regenerative medicine. Its products support scientists in laboratory research and single-cell isolation and analysis.

2 investors

Xcelthera develops cell therapy platform technology, serving the biotech and therapeutic development sector.

2 investors

Cellbricks is a tissue therapeutics company developing cell-based human tissue implants using light-based biofabrication and AI-driven tissue engineering to restore soft tissue defects and organ function. It targets patients with conditions caused by tissue dysfunction that lack reliable treatment options.

2 investors

Cellbricks Therapeutics is a preclinical biotech company developing implantable tissue grafts using proprietary bioprinting technology, biomaterials, and human cells for regenerative medicine applications. The company combines deep tech innovation to restore tissue function at clinical scale across multiple therapeutic programs.

2 investors

CellCentric is a clinical-stage biopharmaceutical company developing inobrodib, an oral small molecule inhibitor of the p300/CBP proteins, for the treatment of multiple myeloma and other cancers. The drug is being evaluated in clinical trials, including in combination with standard-of-care therapies for use in community care settings.

2 investors

CellDom develops CloneXplorer, a live single-cell assay platform combining functional imaging, molecular readouts, and integrated cell retrieval for high-resolution cell analysis. The platform enables CAR T-cell potency testing, antibody/TCR discovery, cell line development, and precision medicine applications for research and therapeutic development teams.

2 investors

Cellfiber is a biotechnology company founded in 2015 that develops cell encapsulation technology and manufacturing techniques to increase production capacity for cell and gene therapies, aiming to make these treatments accessible to more patients.

2 investors

Cellphire Therapeutics develops platelet-based and freeze-dried cellular therapeutics for transfusion medicine, focused on controlling hemorrhage. Through its veterinary subsidiary BodeVet, it also markets freeze-dried platelet products for companion and exotic animals.

2 investors

CellRep develops an AI-powered platform that discovers small molecules to reprogram exhausted immune cells, enhancing their function for therapeutic applications including cancer immunotherapy and chronic viral infections. The company's compounds act on multiple biological layers to restore cellular performance without genetic modification.

2 investors

Cellsonics provides cell dissociation technology for research scientists using acoustic waveforms to isolate cells from tissue with higher biological relevance than conventional methods.

2 investors

cellvie develops Therapeutic Mitochondria Transplantation technology and products for patients requiring mitochondrial treatment. The company combines expertise across science, regulatory affairs, manufacturing, and business to advance this therapeutic platform.

2 investors